Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHERLOC: Seribantumab + Docetaxel in Heregulin-Positive NSCLC
NCT02387216Phase 2Terminated
- Sponsor
- Elevation Oncology, Inc.
- Start
- Feb 2015
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of seribantumab in non-small cell lung cancer (NSCLC), sponsored by Elevation Oncology, Inc.. Started Feb 2015; status: terminated.
02
Drugs
seribantumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02387216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387216.